In an experimental controlled human infection model for RSV, pre-challenge nasal IgA titers against RSV were more clearly associated with protection than serum-neutralizing antibody titers.27 This emphasizes the importance of a potential RSV vaccine to induce mucosal and systemic RSV-specific antibody responses. Here, CD79A is linked to infection.